Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1205-1212

  Bedikian, Agop Y ^a   Silverman, Jeffrey A ^b   Papadopoulos, Nicholas E ^a   Kim, Kevin B ^a   Hagey, Anne E ^a   Vardeleon, Anna ^a   Hwu, Wen Jen ^a   Homsi, Jade ^a   Davies, Michael ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hana Biosciences   (United States)

Author keywords

Clinical pharmacology; clinical research; oncology; pharmacokinetics and drug metabolism; pharmacology

Indexed keywords

ANTIEMETIC AGENT; ANTIPYRETIC AGENT; LIPOSOME; MARQIBO; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART ARREST; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MELANOMA; METASTASIS; METASTATIC MELANOMA; NAUSEA; NAUSEA AND VOMITING; PERIPHERAL EDEMA; PHARMACOKINETICS; SCORING SYSTEM; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCITES; FEMALE; HALF-LIFE; HEPATIC INSUFFICIENCY; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MALE; MELANOMA; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM STAGING; PHARMACEUTICAL VEHICLES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUBULIN MODULATORS; UVEAL NEOPLASMS; VINCRISTINE;

EID: 79960712418     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010381499     Document Type: Article

References (25)

1. Cancer Chemotherapy Handbook. 2 nd ed. Dorr R von Hoff D, ed. Norwalk, Conn: Appleton & Lange ; 1994 :
2. Kufe DB, William RC, Hong NH, et al Cancer Medicine. 7 th ed. Hamilton, Ontario: BC Decker ; 2006 :
3. Noble R, Beer C The Vinca Alkaloids in the Chemotherapy of Malignant Disease. Shedden W, ed. Alburcham, UK: John Sherratt and Sons ; 1968 :
4. Rowinsky EK Cancer Chemotherapy and Biotherapy: Principles and Practice. 2 nd ed. Chabner B Longo DL, ed. New York, NY: Lippincott-Raven ; 1996: 263-296.
5. Cancer: Principles & Practice of Oncology. 5 th ed. DeVita VT Hellman S Rosenberg SA, ed. Philadelphia, Pa: Lippincott-Raven ; 1997 :
6. Bender RA, Castle MC, Margileth DA, Oliverio VT. The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther. 1977 ; 22: 430-435
7. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998 ; 34: 33-46 (Pubitemid 28123378)
8. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther. 1996 ; 59: 32-40 (Pubitemid 26046769)
9. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008 ; 13: 248-260 (Pubitemid 351679900)
10. Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem. 2006 ; 6: 537-552 (Pubitemid 44697112)
11. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999 ; 51: 691-744
12. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol. 1999 ; 17: 697-705 (Pubitemid 29075259)
13. Krishna R, Webb MS, St Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001 ; 298: 1206-1212 (Pubitemid 32761941)
14. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization ; 1979 :
15. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol. 2006 ; 46: 727-737 (Pubitemid 43882796)
16. Guidance for Industry: Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville, Md: US Food and Drug Administration ; 2003 :
17. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol. 1982 ; 8: 215-219 (Pubitemid 12081392)
18. Abbott KL, Harman GS. Combination chemotherapy for disseminated malignant melanoma. Anticancer Drugs. 1995 ; 6: 489-497
19. Lotze MD, Kirkwood JM, Flickinger JC Cancer, Principles & Practice of Oncology. 6 th ed. DeVita V Hellman S Rosenberg SA, ed. New York, NY: Lippincott Williams & Wilkins ; 2001 :
20. Bedikian AY, Papadopoulos NE, Kim KB, et al. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res. 2008 ; 18: 400-404
21. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002 ; 22: 197-224 (Pubitemid 35222732)
22. Shan S, Flowers C, Peltz CD, et al. Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity. Cancer Chemother Pharmacol. 2006 ; 58: 245-255
23. Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. 2009 ; 115: 3475-3482
24. Thomas DA, Kantarjian HM, Stock W, et al. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 ; 115: 5490-5498
25. Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006 ; 106: 120-127 (Pubitemid 43032556)